Compare PPIH & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPIH | SLGL |
|---|---|---|
| Founded | 1909 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.6M | 218.9M |
| IPO Year | 1994 | 2016 |
| Metric | PPIH | SLGL |
|---|---|---|
| Price | $27.92 | $63.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $152.50 |
| AVG Volume (30 Days) | ★ 53.6K | 32.5K |
| Earning Date | 09-09-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.61 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $9.36 | N/A |
| P/E Ratio | $55.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.01 | $28.81 |
| 52 Week High | $36.72 | $97.97 |
| Indicator | PPIH | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 39.39 |
| Support Level | $26.02 | $60.91 |
| Resistance Level | $28.80 | $80.53 |
| Average True Range (ATR) | 1.00 | 4.38 |
| MACD | -0.51 | -0.45 |
| Stochastic Oscillator | 3.74 | 2.91 |
Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in Piping Systems. The company engineers, designs, manufactures, and sells specialty piping systems and leak detection systems. Specialty piping systems of the company include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids, and petroleum products, the coating and insulation of oil and gas gathering and transmission pipelines, and liquid and powder based anti-corrosion coatings applied both to the external and internal surfaces of steel pipe, including shapes such as bends, reducers, tees, and other fittings.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.